Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies (Q37992693)

26 August 2017

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies (English)

1 reference

26 August 2017

1 reference

Ryan P Roop

1

1 reference

PubMed ID

22409464

26 August 2017

Cynthia X Ma

series ordinal

2

1 reference

PubMed ID

22409464

26 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

3

1 reference

26 August 2017

273-292

1 reference

Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells

26 August 2017

1 reference

Membrane receptors for steroid hormones: signal transduction and physiological significance

21 January 2018

1 reference

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

Signaling regulation of genomic and nongenomic functions of estrogen receptors.

21 January 2018

1 reference

Estrogen receptor interaction with estrogen response elements

21 January 2018

1 reference

Estrogen receptor pathways to AP-1.

21 January 2018

1 reference

Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes

21 January 2018

1 reference

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

21 January 2018

1 reference

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

Transcriptional regulation by steroid receptor coactivator phosphorylation

21 January 2018

1 reference

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

21 January 2018

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

Roles for growth factors in cancer progression

21 January 2018

1 reference

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium

21 January 2018

1 reference

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

21 January 2018

1 reference

CI-1033, a pan-erbB tyrosine kinase inhibitor

21 January 2018

1 reference

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

21 January 2018

1 reference

Overcoming endocrine therapy resistance by signal transduction inhibition

21 January 2018

1 reference

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

21 January 2018

1 reference

Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention

21 January 2018

1 reference

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

21 January 2018

1 reference

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

21 January 2018

1 reference

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

21 January 2018

1 reference

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells

21 January 2018

1 reference

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

21 January 2018

1 reference

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

21 January 2018

1 reference

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

21 January 2018

1 reference

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

21 January 2018

1 reference

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

21 January 2018

1 reference

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study

21 January 2018

1 reference

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

21 January 2018

1 reference

Of mice and (wo)men: is this any way to test a new drug?

21 January 2018

1 reference

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

21 January 2018

1 reference

Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail

21 January 2018

1 reference

Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways

21 January 2018

1 reference

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

Structure, regulation and function of PKB/AKT--a major therapeutic target

21 January 2018

1 reference

Potential role of PI3K inhibitors in the treatment of breast cancer.

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.

21 January 2018

1 reference

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

21 January 2018

1 reference

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha

21 January 2018

1 reference

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

21 January 2018

1 reference

A frequent kinase domain mutation that changes the interaction between PI3K and the membrane

21 January 2018

1 reference

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

21 January 2018

1 reference

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

21 January 2018

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

21 January 2018

1 reference

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

Akt kinases in breast cancer and the results of adjuvant therapy

21 January 2018

1 reference

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

21 January 2018

1 reference

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

21 January 2018

1 reference

Elevated insulin receptor content in human breast cancer

21 January 2018

1 reference

Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis

21 January 2018

1 reference

Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis

21 January 2018

1 reference

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

21 January 2018

1 reference

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer

21 January 2018

1 reference

The role of endocrine insulin-like growth factor-I and insulin in breast cancer

21 January 2018

1 reference

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

21 January 2018

1 reference

Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development.

21 January 2018

1 reference

Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action.

21 January 2018

1 reference

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

21 January 2018

1 reference

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

21 January 2018

1 reference

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

21 January 2018

1 reference

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

21 January 2018

1 reference

Customizing the targeting of IGF-1 receptor

21 January 2018

1 reference

Clinical development of inhibitors of the insulin-like growth factor receptor in oncology

21 January 2018

1 reference

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

21 January 2018

1 reference

Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

21 January 2018

1 reference

IGF-1 receptor inhibitors in clinical trials--early lessons

21 January 2018

1 reference

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

21 January 2018

1 reference

Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer

21 January 2018

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

Crosstalk between the insulin-like growth factors and estrogens in breast cancer.

21 January 2018

1 reference

Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells

21 January 2018

1 reference

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

21 January 2018

1 reference

Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1.

21 January 2018

1 reference

Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells

21 January 2018

1 reference

The role of adapter protein Shc in estrogen non-genomic action

21 January 2018

1 reference

Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells.

21 January 2018

1 reference

Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

21 January 2018

1 reference

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line

21 January 2018

1 reference

Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells

21 January 2018

1 reference

Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells

21 January 2018

1 reference

Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

21 January 2018

1 reference

Roles of fibroblast growth factor receptors in carcinogenesis

21 January 2018

1 reference

Structural and Functional Diversity in the FGf Receptor Multigene Family

21 January 2018

1 reference

Potential for targeting the fibroblast growth factor receptors in breast cancer

21 January 2018

1 reference

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

21 January 2018

1 reference

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

21 January 2018

1 reference

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells

21 January 2018

1 reference

Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer

21 January 2018

1 reference

Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss

21 January 2018

1 reference

PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells

21 January 2018

1 reference

Estrogen rapid action via protein complex formation involving ERalpha and Src.

21 January 2018

1 reference

Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway

21 January 2018

1 reference

Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation

21 January 2018

1 reference

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

Targeting Src in breast cancer

21 January 2018

1 reference

Significance of ER-Src axis in hormonal therapy resistance

21 January 2018

1 reference

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically

21 January 2018

1 reference

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

21 January 2018

1 reference

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.

21 January 2018

1 reference

Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

21 January 2018

1 reference

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

21 January 2018

1 reference

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

21 January 2018

1 reference

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

21 January 2018

1 reference

Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response

21 January 2018

1 reference

ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers

21 January 2018

1 reference

Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.

21 January 2018

1 reference

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

21 January 2018

1 reference

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

21 January 2018

1 reference

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

21 January 2018

1 reference

ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

21 January 2018

1 reference

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes

21 January 2018

1 reference

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant

21 January 2018

1 reference

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer

21 January 2018

1 reference

MicroRNAs: genomics, biogenesis, mechanism, and function

21 January 2018

1 reference

MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms

21 January 2018

1 reference

MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer

21 January 2018

1 reference

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies

21 January 2018

1 reference

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.12.8

1 reference

26 August 2017

1 reference

PubMed ID

22409464